Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: A report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group

Transfusion

Volumn 47, Issue 11, 2007, Pages 2072-2080

  Constantine, Maggie M ^b   Thomas, Wanda ^b   Whitman, Lucinda ^b   Kahwash, Eiad ^b   Dolan, Sean ^b   Smith, Susan ^b   Caudle, Christopher J ^b   Burton, Erica ^b   Anderson, David R ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CANADA; DRUG COST; DRUG USE; DRUG UTILIZATION; FEEDBACK SYSTEM; HEMATOLOGIST; HUMAN; IDIOPATHIC DEMYELINATING POLYNEUROPATHY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; MEDICAL SPECIALIST; NEUROLOGIST; POLYNEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION;

CANADA; COOPERATIVE BEHAVIOR; DATA COLLECTION; DRUG LABELING; DRUG UTILIZATION REVIEW; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; POLYRADICULONEUROPATHY; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REGISTRIES;

EID: 35448950419     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01400.x     Document Type: Article

References (12)

1. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005 142 : 1 11.
2. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005 42 : 839 48.
3. Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 2001 11 : 63 74.
4. Sher G, Chiavetta JA, Newman A, et al. Summary of national data on Canadian IVIG usage. Canadian Blood Services Conference 2000 Oct Toronto.
5. IVIG utilization management handbook [monograph on the Internet]. Vancouver : British Columbia Provincial Blood Coordinating Office 2002. Available from: http://www.pbco.ca/index.php?option=com_content&task= view&id=14&Itemid=37
6. Pierce RL, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003 17 : 241 51.
7. Bussel JB, Elder E, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004 91 : 771 8.
8. A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks [monograph on the Internet]. Vancouver : TraQ Program 2004. Available from: http://www.traqprogram.ca/Publications.asp#11
9. Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005 45 : 1640 57.
10. Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol 2003 10 : 11 6.
11. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000 34 : 295 9.
12. Frayha HH, Nuessle SJ, Arishi H, Rayes H, Qunibi WY, Bazarbashi MS. Improving utilization of intravenous immune globulin through concurrent use of an indication form. Eur J Clin Pharmacol 1997 52 : 255 60.